WO2020129366A1 - 健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム - Google Patents
健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム Download PDFInfo
- Publication number
- WO2020129366A1 WO2020129366A1 PCT/JP2019/039818 JP2019039818W WO2020129366A1 WO 2020129366 A1 WO2020129366 A1 WO 2020129366A1 JP 2019039818 W JP2019039818 W JP 2019039818W WO 2020129366 A1 WO2020129366 A1 WO 2020129366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- health risk
- information
- cells
- management device
- information management
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
Definitions
- the present invention relates to a health risk information management device, a health risk information management method, and a program.
- Patent Document 1 For example, a technique for estimating future health risk based on genome information, biological information such as blood pressure, and behavior information such as exercise amount is known. It is hoped that a mechanism will be prepared for future treatment by regenerative medicine in response to such future health risks.
- an object of the present invention is to realize a mechanism that utilizes stem cells to accurately predict future health risks and to prepare for future health risks.
- the health risk information management device an expected health risk information acquisition unit that acquires information about the expected health risk of the user, And a cultured cell production determination unit that determines whether or not to produce a cultured cell derived from the cell of the user based on the information on the expected health risk.
- a health risk information management method includes a step of acquiring information about a user's expected health risk, And a step of determining whether or not to prepare a cultured cell derived from the cell of the user based on the information of the expected health risk.
- a program according to the present invention is a computer An expected health risk information acquisition unit that obtains information about expected health risks of users, Based on the information on the expected health risk, it functions as a cultured cell production determination unit that determines whether or not to produce cultured cells derived from the cells of the user.
- 6 is a flowchart of somatic cell production suggestion processing based on the user's health risk information by the health risk information management device 10 according to the embodiment of the present invention.
- 7 is a flowchart of a health risk proof experiment using somatic cells produced via iPS cells and a proposed process of iPS cell banking based on the results of the proof experiment according to the embodiment of the present invention.
- 6 is a flowchart of a donor search process for HLA homozygotes according to an embodiment of the present invention.
- FIG. 1 is a block diagram showing the configuration of a health risk information management device 10 according to an embodiment of the present invention.
- the health risk information management device 10 includes a control device 11 and an external storage device 12.
- the control device 11 includes, as hardware, a CPU, a memory such as a ROM and a RAM, an input interface, an output interface, and a communication interface.
- the control device 11 realizes various functions by the CPU executing programs stored in the ROM or the like.
- the external storage device 12 is a hard disk drive or the like.
- a customer information database 121 is installed in the external storage device 12.
- the health risk information management device 10 does not have to be composed of one computer, and may be composed of a plurality of computers distributed on a communication network and an external storage device. Further, as shown in FIG. 1, the health risk information management device 10 is connected to the cell production management system 20 and the user terminal 30 via a communication line N.
- FIG. 2 is a block diagram showing functional modules realized by the control device 11 of the health risk information management device 10.
- the function module includes an expected health risk information acquisition unit 101, a somatic cell type determination unit 102, a recommended test content determination unit 103, a somatic cell production instructing unit 104, a test result providing unit 105, a cell production necessity confirmation unit 106, and a health risk.
- Correspondence information providing unit 107, donor candidate extraction unit 108, recipient information acquisition unit 109, HLA compatibility determination unit 110, compatibility information provision unit 111, compatible person number calculation unit 112, donor cell production management unit 113, cultured cell production determination A section 114 is included.
- the customer information database 121 information on users who have registered their own health risk information and iPS cell banking information in the health risk information management device 10 is registered. Specifically, for example, user ID (user identification information), name, sex, date of birth, contact information (email address of the user terminal 30, telephone number, etc.), information regarding genetic tests and health risks, etc. (Diseases with possible diseases, probability of onset, expected time of onset, HLA type, etc.), information on stored iPS cells and somatic cells (identification number, somatic cell type, stored The number of existing products, the time of production, etc.) are included.
- the cell production management system 20 manages the production of iPS cells derived from the user's somatic cells (eg, autologous cells, cells for autologous transplantation).
- the cell production management system 20 is preferably a dedicated device capable of producing iPS cells, but is not limited to this, and manages the production of iPS cells in medical institutions, research institutions, and other production institutions capable of producing iPS cells. Including a system to do.
- Dedicated devices that can create iPS cells include induction, culture, storage, and recording of iPS cells, as well as isolation of somatic cells (isolation of peripheral blood mononuclear cells from blood and fibroblasts from skin pieces).
- At least one or more, preferably two or more of isolation etc.) and expansion culture of the isolated cells can be performed in a closed space without human intervention.
- isolation of user's somatic cells from which cells are made isolation of peripheral blood mononuclear cells from blood, isolation of fibroblasts from skin pieces, etc.
- expansion of isolated cells It is desirable to be able to perform culture and the like.
- the cell production management system 20 may be installed in the same facility as the health risk information management device 10 or may be installed in a different facility.
- the cell production management system 20 introduces an inducing factor into somatic cells collected from a user based on an instruction from the health risk information management apparatus 10 or the like to produce iPS cells, and the quality of the produced iPS cells. Tests (differentiation inducibility test, gene mutation test, fungus/bacteria/virus test, etc.) are carried out to prepare standardized iPS cells. The iPS cells produced in this way are stored in an appropriately temperature-controlled state.
- the cell production management system 20 can produce not only iPS cells but also specific somatic cells from iPS cells. For example, the cell production management system 20 can produce iPS cells from the user's skin tissue and further produce various somatic cells from the produced iPS cells.
- Somatic cells include, for example, neural cells, cardiac muscle, hepatocytes, ⁇ -cells, blood cells, platelets, skin cells, mesenchymal cells and the like. Further, the cell production management system 20 may manage the execution of the health risk proof experiment using somatic cells produced from iPS cells. Further, the cell production management system 20 conducts a verification experiment of compatibility between somatic cells produced from donor candidate iPS cells and recipient blood-derived immune cells based on instructions from the health risk information management apparatus 10. It may be performed.
- the user terminal 30 is a terminal possessed by a user who has registered information in the health risk information management device 10.
- the user terminal 30 is a personal computer (PC), notebook PC, tablet terminal, smartphone, mobile phone, personal digital assistant (PDA), or any other device capable of exchanging data with the health risk information management apparatus 10 via a communication network.
- a terminal device can be used.
- the user terminal 30 includes a processor, an input device such as a keyboard and a mouse, various operation buttons and a touch panel, a display device such as a liquid crystal display, a communication interface for connecting to a communication network, a disk drive or a semiconductor memory (ROM, RAM, etc.). It is equipped with storage resources such as.
- the health risk information management device 10 first acquires information on the expected health risk of the user (S101).
- the information on the expected health risk is, for example, information estimated based on the result of the genetic test. Genetic tests include those that use genomic information such as whole exome sequence (WES), whole genome sequence (WGS), and SNP array, and tests that determine gene expression information, microRNA expression information, HLA type, etc. Those that use sequences etc. are included.
- the expected health risk includes information about a disease that a user (test subject) and his/her family may develop in the future and a probability of developing the disease.
- the information on the expected health risk may be acquired from a system such as an institution that carries out a genetic test via a communication line, or an engineer or manager who operates the health risk information management device 10 may check the information of the user. You may make it input, referring to data.
- the health risk information management device 10 determines the type of somatic cells to be produced from the cultured cells derived from the cells of the user in order to verify the acquired expected health risk of the user (S102).
- the cultured cells are specifically iPS cells, but may be other stem cells, pluripotent stem cells, or somatic stem cells.
- the cultured cells are specifically iPS cells, but may be other stem cells, pluripotent stem cells, or somatic stem cells.
- nerve cells in the case of having a high risk of developing rheumatism, cells of cartilage tissue, a high risk of developing myocardial infarction is expected.
- cardiomyocytes are determined as somatic cells to be produced.
- the health risk is not limited to a specific disease name, and includes, for example, information that UV resistance of the skin is weak and that the skin is easily dried when exposed to ultraviolet rays. In this case, the skin cells are determined as the somatic cells to be produced.
- the health risk information management device 10 determines the content of the inspection to be performed using the prepared somatic cells in order to verify the expected health risk of the user (S103). For example, when the risk of developing Alzheimer's disease is high, an experiment is conducted in which the prepared nerve cells are exposed to hydrogen peroxide or the like to confirm their vulnerability to oxidative stress. Further, when the risk of developing rheumatism is high, an experiment is carried out to confirm whether or not the symptoms of rheumatism appear using the cells of the cartilage tissue prepared. When the risk of developing myocardial infarction is expected to be high, an experiment is conducted to verify whether or not myocardial infarction actually occurs using the prepared cardiomyocytes.
- the prepared skin cells are irradiated with UV to confirm the reaction, or a drying test is performed to confirm the weakness to dryness.
- it is also effective for demonstrating high risk of ALS (Amyotrophic Lateral Sclerosis), Parkinson's disease, skin disease, nerve disease, eye disease, heart disease, liver disease, kidney disease, blood disease, etc. is there.
- the responsiveness ex. allergic reaction and hypersensitivity
- You may verify whether it is effective. In this way, using somatic cells that have actually been prepared, the susceptibility to diseases and symptoms, and effective treatment and prevention methods are verified.
- the risk of GVHD graft-versus-host disease after transplantation may be verified.
- the health risk information management device 10 transmits, to the user terminal 30 of the user, information on somatic cells to be produced in order to perform a test for verifying the expected health risk (S104), and A response is received as to whether or not the production and the test are desired to be performed (S105).
- the health risk information management device 10 When the health risk information management device 10 receives a response indicating that the production of somatic cells and the execution of the test are desired (S106: YES), it sends a somatic cell production instruction to the cell production management system 20 (S107).
- the user's iPS cells are first produced (S201), and then the somatic cells for conducting a health risk demonstration experiment are produced via the iPS cells (S202).
- the produced iPS cells and somatic cells are managed by attaching tags (identification numbers).
- the iPS cell and somatic cell tag information is also supplied to the health risk information management device 10 and registered in the customer information database 121 (S203).
- an experiment of a pathological condition reproduction model is carried out using the somatic cells produced by the cell production management system 20 (S204). Specifically, an experiment is performed to verify with what probability the disease that is predicted to be at risk develops according to the content determined in step S103. It also predicts the time to disease onset. Further, the prepared somatic cells are used to screen a drug or a combination of drugs effective in improving the condition (S205). Specifically, we will verify what kind of drug is effective, what kind of combination of drugs is effective, and whether the drug is toxic or allergic. Experimental results (probability of onset, expected period until onset) by the pathological condition reproduction model and information on the result of drug screening are registered in the customer information database 121.
- the health risk information management apparatus 10 recommends, based on the result of an experiment using a pathological condition reproduction model, a preparation time for recommending iPS cells or somatic cells prepared from iPS cells in advance in preparation for a case where a disease actually occurs in the future, and The effect (probability) of eliminating health risks by producing somatic cells is calculated (S206).
- the health risk information management device 10 transmits the result of the verification experiment conducted using somatic cells (probability of onset, expected period until onset) to the user terminal 30 of the user (S207). In addition to the test results, information on somatic cells that should be prepared and stored in case of future onset of disease, recommended preparation time, and information quantifying the effects of the preparation of the somatic cells. , At least one is also provided (S208). Further, the health risk information management device 10 displays information on a necessary treatment cost based on the expected period until the onset of the disease and a plan (including a reserve plan) of the treatment cost according to the period until the occurrence of the disease. Provide at least one of them.
- an HLA type is selected from among users who manage data in the health risk information management apparatus 10 in response to a request from a donor who desires to provide somatic cells (hereinafter, a recipient). Search for a matching donor.
- the recipient may be a user whose data is managed by the health risk information management device 10 or an unregistered user.
- a search for a donor with which the HLA type is compatible may be performed using another database.
- the health risk information management device 10 extracts the users of the HLA homozygotes from the users registered in the customer information database 121 (S301). The extracted users become donor candidates. In addition to users registered in the customer information database 121, data managed by genetic testing companies, prenatal diagnosis data, data managed by bone marrow banks, HLA typing database, etc. are used for HLA. Candidate donors may be extracted from the users who have recorded the above information.
- the health risk information management apparatus 10 acquires the HLA type information of the recipient (S302), and extracts a donor candidate whose HLA type matches the recipient from the extracted donor candidates (S303). ). It should be noted that the extraction of the donor candidate may be performed by extracting the person whose HLA type is similar to that of the recipient regardless of whether or not it is an HLA homozygote.
- the health risk information management device 10 may provide the recipient with information on the donor candidate to which the HLA type is compatible (S304). Specifically, it may be sent by e-mail to the user terminal 30 possessed by the recipient, or may be printed out as a report.
- a verification experiment of compatibility is carried out by mixing somatic cells prepared from the donor candidate iPS cells and recipient blood-derived immune cells in vitro. (S305).
- the compatibility verification experiment may be performed by the cell production management system 20 based on an instruction from the health risk information management device 10. Alternatively, the worker may carry out the work based on the work instruction presented by the health risk information management device 10.
- the result of the compatibility experiment may be provided to the recipient via the health risk information management device 10 (S306).
- information about the health risk of the donor (how likely and what kind of disease may develop) may be provided.
- the health risk information management apparatus 10 determines that the HLA type is suitable for each user (donor candidate) of the HLA homozygote, based on the data obtained by the donor search processing requested by many recipients. You may make it calculate the number of recipients who obtained the result of. Furthermore, for each donor candidate, how much iPS cells of the donor candidate are required is calculated based on the number of recipients to which the HLA type matches, and the calculation result is provided to the cell production management system 20. May be. The cell production management system 20 can produce and expand iPS cells of each donor candidate based on the calculation result.
- the health risk information management device 10 cultures derived from the user's cells (including somatic cells, stem cells, mesenchymal stem cells, blood cells, epithelial cells, etc.) based on the acquired information on the expected health risk of the user. It also has a function of determining whether or not to make cells. Similar to the above embodiment, the cultured cells are specifically iPS cells, but may be other stem cells, pluripotent stem cells, or somatic stem cells. This makes it possible to accurately determine whether or not the iPS cells should be prepared and stored, depending on the possibility of the future health risk of the user, the degree of seriousness, and the like.
- cases in which it is judged effective to prepare iPS cells include, for example, cases in which effective treatment can be performed using iPS cells when a disease actually develops.
- the stock of iPS cell may be increased for other related persons. May be determined to be valid.
- the cell production may include cell initialization, reprogramming, cell fate conversion, and cell transformation.
- the health risk information management device 10 also has a function of determining whether or not to produce cells derived from the somatic cells of the user based on the HLA type information of the user. Specifically, a user of HLA homozygote may be a donor, and thus it may be judged that the production and storage of iPS cells are effective.
- efficient and appropriate advice can be provided by determining whether or not a user is advised to make and store iPS cells based on the expected health risk based on genetic tests and information on HLA type. You can In particular, since the production and storage of iPS cells are expensive, accurate advice based on accurate information is important. Moreover, since the production of iPS cells of a person who really needs it can be prioritized, resources such as the cell production management system 20 can be effectively used.
- the type of somatic cells to be produced from the iPS cells derived from the somatic cells of the user is determined in order to demonstrate the expected health risk of the user based on the genomic information and the like. , It is possible to provide a mechanism for performing a test for demonstrating an expected health risk using the produced somatic cells. This makes it possible to utilize iPS cells and accurately predict future health risks.
- the user After providing the user with information on somatic cells necessary for the test, the user accepts whether iPS cells or somatic cells derived from iPS cells are desired to be produced and tested, and responds to the request.
- the system for instructing the cell production management system 20 to produce somatic cells is realized. As a result, it is possible to efficiently manage the production of iPS cells and the execution of tests according to the user's wishes.
- somatic cells In addition, based on the results of tests using somatic cells, information on somatic cells that should be prepared and stored by the user in case of future disease outbreak, recommended preparation time, preparation of the somatic cells I tried to provide information that quantified the effect of. As a result, the user can obtain information for making a judgment when appropriately preparing for future health risks. Specifically, it is a criterion for deciding whether or not to prepare and store its own iPS cells for the future.
- somatic cells produced were used to verify drugs and drug combinations that are effective in improving expected health risks, and to provide information to users. Can be used.
- a mechanism for extracting users of HLA homozygotes as donor candidates, and extracting donor candidates whose donors want to provide somatic cells from donors and whose HLA type is compatible are extracted from the donor candidates. It was realized. This makes it possible to efficiently search for a donor whose HLA type matches the recipient.
- a mechanism for verifying the compatibility by using immune cells derived from the blood of the recipient and somatic cells derived from the iPS cells of the donor candidate whose HLA type has been matched with the recipient has been realized. Somatic cells can be provided from the donor after verifying immune rejection in advance.
- the extraction of the donor candidate may be performed by extracting the person whose HLA type is similar to that of the recipient regardless of whether or not it is an HLA homozygote. For example, as one example, there are about 15 types of HLA, and generally, if 4 of them are compatible, weak immunosuppressants can be used, and if 6 of them are compatible, an immunosuppressant is required. It is believed that there is no. Therefore, the donor candidate may be extracted based on the information on how many types of HLA match. The criterion for determining whether the HLA types are similar is not limited to this.
- the iPS cells stored in the cell production management system 20 may be extracted to have the same or similar HLA type. It may also be used to verify whether cells of the selected HLA type exert an effect of suppressing GVHD.
- the number of recipients to which the HLA type is compatible may be managed. Furthermore, based on the number of recipients to which the HLA type matches, how much cultured cells derived from the cells of each donor candidate are calculated, and the iPS cells of each donor candidate are prepared based on the calculation results. You may do it. Thus, the iPS cells and somatic cells can be prepared systematically so that the recipient can receive the somatic cells from the donor whose HLA type matches.
- the prediction accuracy should be improved by using deep learning and AI (artificial intelligence). You can
- Health risk information management device 11 Control device 12... External storage device 20... Cell production management system 30... User terminal 101... Expected health risk information acquisition unit 102... Somatic cell type determination unit 103... Recommended examination content determination unit 104 Somatic cell production instructing unit 105... Test result providing unit 106... Cell production necessity confirmation unit 107... Health risk correspondence information providing unit 108... Donor candidate extraction unit 109... Recipient information acquisition unit 110... HLA conformity determination unit 111... Conformance Sex information providing unit 112... Matching number calculation unit 113... Donor cell production management unit 114... Cultured cell production determination unit 121... Customer information database
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
そこで本発明の目的は、幹細胞を活用し、将来の健康リスクを精確に予測すると共に、将来の健康リスクへの備えにつなげる仕組みを実現することである。
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する培養細胞作製判定部と、を備えたものである。
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する工程と、を含むものである。
利用者の予想健康リスクに関する情報を取得する予想健康リスク情報取得部と、
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する培養細胞作製判定部と、して機能させるものである。
図1は、本発明の実施の形態による健康リスク情報管理装置10の構成を示すブロック図である。図1に示すように、健康リスク情報管理装置10は、制御装置11と、外部記憶装置12を備えている。
次に、健康リスク情報管理装置10による利用者の健康リスク情報に基づく、体細胞作製の提案処理について図3のフローチャートを用いて説明する。
次に、iPS細胞を介して作製した体細胞を用いた健康リスクの実証実験と、実証実験の結果に基づくiPS細胞のバンキングの提案処理について図4のフローチャートを用いて説明する。なお、図4に示すS201~S205の各ステップは、細胞作製管理システム20によって自動的に実施される。また、細胞作製管理システム20によって作業フローが自動的に作成され、細胞作製管理システム20から提示される作業指示に基づいて作業者が実施するようにしてもよい。
まず、健康リスク情報管理装置10は、顧客情報データベース121に登録されている利用者の中から、HLAホモ接合体の利用者を抽出する(S301)。抽出した利用者は、ドナー候補者となる。なお、顧客情報データベース121に登録されている利用者以外にも、遺伝子検査会社の管理するデータや出生前診断のデータ、骨髄バンクで管理するデータ,HLAタイピングデーターベース等を利用し、それらにHLAの情報が記録されている利用者の中からドナー候補者を抽出してもよい。
健康リスク情報管理装置10は、取得した利用者の予想健康リスクに関する情報に基づいて、利用者の細胞(体細胞、幹細胞、間葉系幹細胞、血液細胞、上皮細胞等を含む)に由来する培養細胞を作製するか否かを判断する機能も有する。上記の実施の形態と同様に、培養細胞は具体的にはiPS細胞であるが、他の幹細胞、多能性幹細胞、体性幹細胞であってもよい。これにより、利用者の将来の健康リスクの可能性の高さや深刻度などに応じて、iPS細胞を作製して保存しておくべきか否かを的確に判断することができる。iPS細胞を準備しておくことが有効と判断される例としては、例えば、実際に疾患が発症した際にiPS細胞を利用して有効な治療が行える場合などがあげられる。また、血縁関係者間で遺伝する傾向の強い疾患の場合、親や兄弟などの血縁関係者にそれらの疾患のリスクがある場合には、血縁関係者である他の者についてもiPS細胞のストックが有効であるとの判定結果を出すようにしてもよい。なお、細胞の作製には、細胞の初期化、リプログラミング、細胞の運命転換、細胞の形質転換も含むようにしてもよい。
11…制御装置
12…外部記憶装置
20…細胞作製管理システム
30…利用者端末
101…予想健康リスク情報取得部
102…体細胞種類決定部
103…推奨検査内容決定部
104…体細胞作製指示部
105…検査結果提供部
106…細胞作製要否確認部
107…健康リスク対応情報提供部
108…ドナー候補抽出部
109…レシピエント情報取得部
110…HLA適合判定部
111…適合性情報提供部
112…適合者数算出部
113…ドナー細胞作製管理部
114…培養細胞作製判定部
121…顧客情報データベース
Claims (23)
- 利用者の予想健康リスクに関する情報を取得する予想健康リスク情報取得部と、
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する培養細胞作製判定部と、を備えた健康リスク情報管理装置。 - 前記予想健康リスク情報取得部は、利用者の遺伝子検査の情報に基づく、予想健康リスクに関する情報を取得する、請求項1に記載の健康リスク情報管理装置。
- 前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞から作製すべき体細胞の種類を決定する体細胞種類決定部を備えた請求項1または2に健康リスク情報管理装置。
- 前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞から作製された体細胞を用いて行うべき検査の内容を決定する推奨検査内容決定部を備えた請求項3に記載の健康リスク管理装置。
- 細胞の作製を管理するシステムに、体細胞の作製指示を送信する体細胞作製指示部と、
作製された体細胞を用いて実施された前記検査の結果を、前記利用者に提供する検査結果提供部と、を備えた請求項4に記載の健康リスク情報管理装置。 - 前記作製すべき体細胞情報を前記利用者に提供し、体細胞の作製を希望するか否かの回答を受け付ける細胞作製要否確認部を備え、
前記体細胞作製指示部は、
体細胞の作製を希望する旨の回答を受け付けた場合には、前記体細胞の作製を管理するシステムに、当該体細胞の作製指示を送信する、請求項5に記載の健康リスク情報管理装置。 - 前記細胞作製要否確認部は、
前記培養細胞の作製を希望するか否かの回答を受け付ける、請求項6に記載の健康リスク情報管理装置。 - 前記検査の結果に基づいて、前記利用者の予想健康リスクに対する予防策、および予想健康リスクが発生した場合の対応策に関する情報を提供する健康リスク対応情報提供部を備えた、請求項5に記載の健康リスク情報管理装置。
- 前記健康リスク対応情報提供部は、
前記作製された体細胞を用いてスクリーニングした、前記予想健康リスクの改善に効果的な薬剤の情報、または薬剤の毒性と薬剤に対する応答性の情報の少なくとも一方を提供する、請求項8に記載の健康リスク情報管理装置。 - 前記健康リスク対応情報提供部は、
前記検査の結果に基づいて、前記利用者の細胞に由来する培養細胞から作製しておくべき体細胞の種類の情報を提供する、請求項8に記載の健康リスク情報管理装置。 - 前記健康リスク対応情報提供部は、
前記検査の結果に基づいて、当該利用者が将来に備えて作製して保存しておくべき体細胞の情報と、推奨する作製時期と、当該体細胞の作製による効果を数値化した情報を提供する、請求項8に記載の健康リスク情報管理装置。 - 前記健康リスク対応情報提供部は、
前記検査の結果に基づいて、当該利用者が作製して保存しておくべき前記培養細胞に関する情報を提供する、請求項8に記載の健康リスク情報管理装置。 - 前記健康リスク対応情報提供部は、
前記検査の結果に基づいて、前記健康リスクの発生までの期間を予測し、必要な治療費用と、発生までの期間に応じた支払いのプランの情報を提供する、請求項8に記載の健康リスク情報管理装置。 - 利用者のHLA型の情報に基づいて、HLAホモ接合体の利用者をドナー候補者として抽出するドナー候補抽出部を備え、
前記培養細胞作製判定部は、
利用者がHLAホモ接合体であるか否かに基づいて、当該利用者の細胞に由来する培養細胞を作製するか否かを判断する請求項1に記載の健康リスク情報管理装置。 - HLA型が適合するドナーからの体細胞の提供を希望するレシピエントのHLA型の情報を取得するレシピエント情報取得部と、
前記抽出されたHLAホモ接合体のドナー候補者の中から、前記レシピエントとHLA型が適合するドナー候補者を抽出するHLA適合判定部と、を備えた請求項14に記載の健康リスク情報管理装置。 - 前記レシピエントの血液由来の免疫細胞と、前記レシピエントとHLA型が適合したドナー候補者のiPS細胞またはiPS細胞由来の体細胞を用いて行われた適合性の検証結果を、前記レシピエントに提供する、適合性情報提供部を備えた請求項15に記載の健康リスク情報管理装置。
- 各々のドナー候補者について、HLA型が適合するレシピエントの数を算出する、適合者数算出部を備えた、請求項14記載の健康リスク情報管理装置。
- 各々のドナー候補者について、HLA型が適合するレシピエントの数に基づいて、当該ドナー候補者の細胞に由来する培養細胞がどのぐらい必要かを算定する、ドナー細胞作製管理部を備えた請求項14に記載の健康リスク情報管理装置。
- 前記HLA適合判定部は、
利用者のHLA型の情報に基づいて、保存されている培養細胞の中からHLA型が適合するものを抽出する、請求項15に記載の健康リスク情報管理装置。 - 前記HLA適合判定部は、
複数種類のHLAのうち、所定数の種類のHLAが適合する場合には、HLA型が適合すると判定する請求項15に記載の健康リスク情報管理装置。 - 前記細胞に由来する培養細胞は幹細胞である、請求項1から20のいずれか1項に記載の健康リスク情報管理装置。
- 利用者の予想健康リスクに関する情報を取得する工程と、
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する工程と、を含む健康リスク情報管理方法。 - コンピュータを、
利用者の予想健康リスクに関する情報を取得する予想健康リスク情報取得部と、
前記予想健康リスクの情報に基づいて、前記利用者の細胞に由来する培養細胞を作製するか否かを判断する培養細胞作製判定部と、して機能させるプログラム。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19900951.5A EP3901959A4 (en) | 2018-12-21 | 2019-10-09 | HEALTH RISK INFORMATION MANAGEMENT DEVICE, METHOD AND PROGRAM |
US17/416,330 US20220076839A1 (en) | 2018-12-21 | 2019-10-09 | Health risk information management device, health risk information management method, and program |
CA3124069A CA3124069A1 (en) | 2018-12-21 | 2019-10-09 | Health risk information management device, health risk information management method, and program |
JP2020561174A JPWO2020129366A1 (ja) | 2018-12-21 | 2019-10-09 | 健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム |
CN201980073644.4A CN112955963A (zh) | 2018-12-21 | 2019-10-09 | 健康风险信息管理装置、健康风险信息管理方法及程序 |
SG11202106673XA SG11202106673XA (en) | 2018-12-21 | 2019-10-09 | Health risk information management device, health risk information management method, and program |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018239868 | 2018-12-21 | ||
JP2018-239868 | 2018-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020129366A1 true WO2020129366A1 (ja) | 2020-06-25 |
Family
ID=71100763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/039818 WO2020129366A1 (ja) | 2018-12-21 | 2019-10-09 | 健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220076839A1 (ja) |
EP (1) | EP3901959A4 (ja) |
JP (1) | JPWO2020129366A1 (ja) |
CN (1) | CN112955963A (ja) |
CA (1) | CA3124069A1 (ja) |
SG (1) | SG11202106673XA (ja) |
WO (1) | WO2020129366A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016062514A (ja) * | 2014-09-20 | 2016-04-25 | 光俊 秋谷 | iPS細胞因子及びまたは各種幹細胞、T細胞、樹状細胞等から解析した遺伝子データ及びまたは細胞周期予測データを再生医療に応用することを特徴とする社会保障システム。 |
JP2016066138A (ja) * | 2014-09-24 | 2016-04-28 | 富士フイルム株式会社 | 診療支援装置、診療支援装置の作動方法および作動プログラム、並びに診療支援システム |
JP2017097895A (ja) | 2013-10-01 | 2017-06-01 | 国立大学法人東北大学 | 健康情報表示装置及び方法 |
WO2018155570A1 (ja) * | 2017-02-27 | 2018-08-30 | アイ ピース, インコーポレイテッド | 保険管理システム及びその方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091936A1 (en) * | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
EP1817708A4 (en) * | 2004-10-18 | 2014-08-27 | Wellstat Vaccines Llc | SYSTEMS AND METHODS FOR OBTAINING, STORING, PROCESSING AND USING IMMUNOLOGICAL INFORMATION RELATING TO AN INDIVIDUAL OR A POPULATION |
US8759090B2 (en) * | 2006-10-30 | 2014-06-24 | University Of Central Florida Research Foundation, Inc. | Stem cell banking system |
US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
WO2009152485A2 (en) * | 2008-06-13 | 2009-12-17 | Ipierian, Inc. | Methods of cell-based technologies |
WO2011138786A2 (en) * | 2010-05-06 | 2011-11-10 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
JP6861481B2 (ja) * | 2016-07-06 | 2021-04-21 | オムロンヘルスケア株式会社 | リスク分析システム及びリスク分析方法 |
TW201835801A (zh) * | 2017-02-24 | 2018-10-01 | 美商歐瑞3恩公司 | 使用不朽誘導多能幹細胞作為用於無限壽命遺傳分析、組織創建、療法選擇判定及實驗室培養皿應用(lab-in-a-dish)之平台之系統及方法 |
WO2018170046A1 (en) * | 2017-03-14 | 2018-09-20 | Orig3N, Inc. | Hla-indexed repository of ipscs and ipsc-derived stem cells, and related systems and methods |
AU2018324301A1 (en) * | 2017-09-01 | 2020-04-16 | Orig3N, Inc. | I-PSC derived secretome compositions, and related systems and methods |
CN108364677B (zh) * | 2018-03-13 | 2021-06-18 | 汤臣倍健股份有限公司 | 一种基于多维度健康管理模型的评测方法及其装置 |
US20220028488A1 (en) * | 2018-12-07 | 2022-01-27 | President And Fellows Of Harvard College | Drug discovery and early disease identification platform using electronic health records, genetics and stem cells |
-
2019
- 2019-10-09 SG SG11202106673XA patent/SG11202106673XA/en unknown
- 2019-10-09 WO PCT/JP2019/039818 patent/WO2020129366A1/ja unknown
- 2019-10-09 CN CN201980073644.4A patent/CN112955963A/zh active Pending
- 2019-10-09 EP EP19900951.5A patent/EP3901959A4/en active Pending
- 2019-10-09 CA CA3124069A patent/CA3124069A1/en active Pending
- 2019-10-09 US US17/416,330 patent/US20220076839A1/en active Pending
- 2019-10-09 JP JP2020561174A patent/JPWO2020129366A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017097895A (ja) | 2013-10-01 | 2017-06-01 | 国立大学法人東北大学 | 健康情報表示装置及び方法 |
JP2016062514A (ja) * | 2014-09-20 | 2016-04-25 | 光俊 秋谷 | iPS細胞因子及びまたは各種幹細胞、T細胞、樹状細胞等から解析した遺伝子データ及びまたは細胞周期予測データを再生医療に応用することを特徴とする社会保障システム。 |
JP2016066138A (ja) * | 2014-09-24 | 2016-04-28 | 富士フイルム株式会社 | 診療支援装置、診療支援装置の作動方法および作動プログラム、並びに診療支援システム |
WO2018155570A1 (ja) * | 2017-02-27 | 2018-08-30 | アイ ピース, インコーポレイテッド | 保険管理システム及びその方法 |
Also Published As
Publication number | Publication date |
---|---|
US20220076839A1 (en) | 2022-03-10 |
EP3901959A1 (en) | 2021-10-27 |
SG11202106673XA (en) | 2021-07-29 |
EP3901959A4 (en) | 2023-01-04 |
JPWO2020129366A1 (ja) | 2021-11-04 |
CN112955963A (zh) | 2021-06-11 |
CA3124069A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dzobo et al. | Integrating artificial and human intelligence: a partnership for responsible innovation in biomedical engineering and medicine | |
Eddy et al. | Integrated multi-omics approaches to improve classification of chronic kidney disease | |
Manolio et al. | Bedside back to bench: building bridges between basic and clinical genomic research | |
Mecham et al. | Supervised normalization of microarrays | |
Nalls et al. | Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk | |
Dawson et al. | R/EBcoexpress: an empirical Bayesian framework for discovering differential co-expression | |
Martin et al. | Hidden ‘risk’in polygenic scores: clinical use today could exacerbate health disparities | |
Sak et al. | Population biobanking in selected European countries and proposed model for a Polish national DNA bank | |
Iqbal et al. | Reimagining healthcare: unleashing the power of artificial intelligence in medicine | |
Lloyd-Puryear et al. | Foundation of the Newborn Screening Translational Research Network and its tools for research | |
Athreya et al. | Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments? | |
CN109791795A (zh) | 用于协同变异选择和治疗匹配报告的方法和装置 | |
Bemmels et al. | Mapping the inputs, analyses, and outputs of biobank research systems to identify sources of incidental findings and individual research results for potential return to participants | |
Sethi et al. | Translational bioinformatics and healthcare informatics: computational and ethical challenges | |
Costa | Systems pathology: A critical review | |
WO2020129366A1 (ja) | 健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム | |
Wood | The role, duties and responsibilities of technologists in the clinical laboratory | |
Kong et al. | Multidisciplinary effort to drive precision-medicine for the future | |
Nelson et al. | The social life of DTC genetics: The case of 23andMe | |
Ntai et al. | Biobanking shifts to “precision medicine” | |
Driessen et al. | Research projects in human genetics in Switzerland: analysis of research protocols submitted to cantonal ethics committees in 2018 | |
Jamal et al. | Queering genomics: How cisnormativity undermines genomic science | |
Schwartz et al. | A model for genome-first care: returning secondary genomic findings to participants and their healthcare providers in a large research cohort | |
Brand et al. | Biobanking for public health | |
Kaul | Multiscale computational modeling offers key to understanding molecular logic underpinning development and disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19900951 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020561174 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3124069 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019900951 Country of ref document: EP Effective date: 20210721 |